



(51) International Patent Classification:

A61P 27/12 (2006.01) *G01N 33/68* (2006.01)
A61K 31/575 (2006.01) *A61K 47/48* (2006.01)
A61K 31/045 (2006.01)

(21) International Application Number:

PCT/US2013/050866

(22) International Filing Date:

17 July 2013 (17.07.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/672,569 17 July 2012 (17.07.2012) US

(71) Applicant: **REGENTS OF THE UNIVERSITY OF MICHIGAN** [US/US]; Office Of Technology Transfer, 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109-2590 (US).

(72) Inventor: **GESTWICKI, Jason, E.**; 594 Kelmore St., Moss Beach, CA 94038 (US).

(74) Agents: **DOLA, Kristen, A.** et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: NON-SURGICAL METHOD OF TREATMENT FOR CATARACT

(57) Abstract: The invention provides inhibitors of cc-crystallin aggregation and methods of using cc-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (T_m) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent T_m by at least 2 standard deviations is identified as a pharmacological protein chaperone.



WO 2014/015024 A2